Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeiGene Ltd ( (HK:6160) ) just unveiled an announcement.
BeOne Medicines Ltd., a company incorporated under Swiss law, has announced a post-effective amendment to its Form S-8 registration statement filed with the U.S. Securities and Exchange Commission. This amendment pertains to various share option and incentive plans, reflecting the company’s ongoing regulatory compliance and commitment to maintaining transparent financial operations. The announcement highlights the company’s active engagement with international regulatory standards, which may bolster its credibility and attractiveness to investors.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,789,106
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$236.3B
For detailed information about 6160 stock, go to TipRanks’ Stock Analysis page.